Dr. Reddy's Laboratories has completed the acquisition of select portfolio of UCB in India. In April, Dr. Reddy's had announced plans to acquire certain products of Brussels-based biophar-maceutical company UCB in India, Nepal, Sri Lanka and Maldives for Rs. 800-crore. The revenues of the acquired business stood at around Rs. 150-crore in calendar year 2014. The acquisition of UCB portfolio is expected to accelerate Dr. Reddy's presence in the areas of dermatology, respiratory and paediatrics diseases with market leading brands such as Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M, and so on, besides enhancing its focus on key neurology portfolio in India.
展开▼
